EverSource Wealth Advisors LLC Buys 390 Shares of Bruker Co. (NASDAQ:BRKR)

EverSource Wealth Advisors LLC boosted its stake in Bruker Co. (NASDAQ:BRKR) by 41.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,330 shares of the medical research company’s stock after purchasing an additional 390 shares during the period. EverSource Wealth Advisors LLC’s holdings in Bruker were worth $78,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of the business. FMR LLC grew its position in shares of Bruker by 21.4% during the 3rd quarter. FMR LLC now owns 14,306,122 shares of the medical research company’s stock valued at $987,981,000 after acquiring an additional 2,521,904 shares during the period. State Street Corp grew its position in shares of Bruker by 9.6% during the 3rd quarter. State Street Corp now owns 3,627,300 shares of the medical research company’s stock valued at $250,501,000 after acquiring an additional 318,808 shares during the period. RTW Investments LP grew its position in shares of Bruker by 1.1% during the 3rd quarter. RTW Investments LP now owns 3,481,119 shares of the medical research company’s stock valued at $240,406,000 after acquiring an additional 37,024 shares during the period. Geode Capital Management LLC grew its position in shares of Bruker by 10.8% during the 3rd quarter. Geode Capital Management LLC now owns 1,993,468 shares of the medical research company’s stock valued at $137,702,000 after acquiring an additional 193,580 shares during the period. Finally, Vaughan Nelson Investment Management L.P. grew its position in shares of Bruker by 140.3% during the 4th quarter. Vaughan Nelson Investment Management L.P. now owns 1,141,762 shares of the medical research company’s stock valued at $66,930,000 after acquiring an additional 666,617 shares during the period. Institutional investors own 79.52% of the company’s stock.

Bruker Stock Up 0.4 %

Shares of BRKR stock opened at $47.14 on Wednesday. The stock has a market cap of $7.15 billion, a P/E ratio of 62.03, a PEG ratio of 2.16 and a beta of 1.18. Bruker Co. has a 52 week low of $44.11 and a 52 week high of $94.86. The company has a quick ratio of 0.77, a current ratio of 1.60 and a debt-to-equity ratio of 1.15. The company’s fifty day simple moving average is $53.10 and its two-hundred day simple moving average is $58.07.

Bruker (NASDAQ:BRKR) last announced its quarterly earnings results on Thursday, February 13th. The medical research company reported $0.76 EPS for the quarter, topping the consensus estimate of $0.75 by $0.01. Bruker had a net margin of 3.36% and a return on equity of 21.01%. Analysts predict that Bruker Co. will post 2.69 EPS for the current fiscal year.

Bruker Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 28th. Stockholders of record on Monday, March 17th will be given a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a dividend yield of 0.42%. The ex-dividend date of this dividend is Monday, March 17th. Bruker’s dividend payout ratio is 26.32%.

Wall Street Analysts Forecast Growth

BRKR has been the subject of a number of recent research reports. Barclays cut their price objective on shares of Bruker from $69.00 to $65.00 and set an “overweight” rating for the company in a research report on Monday, February 10th. The Goldman Sachs Group raised shares of Bruker from a “sell” rating to a “neutral” rating and set a $60.00 target price for the company in a report on Thursday, December 5th. Guggenheim reaffirmed a “buy” rating on shares of Bruker in a report on Monday, February 24th. Bank of America upped their target price on shares of Bruker from $78.00 to $80.00 and gave the stock a “buy” rating in a report on Friday, December 13th. Finally, UBS Group started coverage on shares of Bruker in a report on Tuesday, December 10th. They issued a “neutral” rating and a $66.00 target price for the company. Six research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $70.50.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.